Responsiveness and MID of 4MGS in IPF
Research type
Research Study
Full title
Responsiveness of the 4 metre gait speed (4MGS) in patients with idiopathic pulmonary fibrosis (IPF) and determination of the minimum important difference (MID)
IRAS ID
166684
Contact name
William Man
Contact email
Sponsor organisation
Royal Brompton and Harefield NHS Foundation Trust
Duration of Study in the UK
2 years, 11 months, 31 days
Research summary
This study is investigating a simple test of usual walking speed, measured using the 4 metre gait speed (4MGS) test in patients with a lung disease called Idiopathic Pulmonary Fibrosis (IPF). Drug development for this disease is slow in part because there is a lack of reliable measurements that can assess effectiveness of treatment. Slow walking speed has been shown to relate to poor outcomes in older adults and people with another lung disease called Chronic Obstructive Pulmonary Disease (COPD). We are interested to see whether usual walking speed in IPF patients changes following a treatment called pulmonary rehabilitation (an exercise and education programme for patients with lung disease) and if it changes, what is the smallest change that is meaningful to patients (the minimum important difference - MID). We are also investigating whether the change in walking speed can predict survival, number of hospital admissions and lung disease progression. This will help inform us of the potential use of 4MGS as an outcome measure. To do this, participants who consent to taking part in the study will be timed walking at their usual walking speed over a distance of 4 metres (13.12 feet) before and after a course of pulmonary rehabilitation.
REC name
London - Riverside Research Ethics Committee
REC reference
14/LO/2247
Date of REC Opinion
10 Feb 2015
REC opinion
Further Information Favourable Opinion